Comparison of Outpatient Systemic Antibacterial Use in 2004 in the United States and 27 European Countries
- Herman Goossens1,3,
- Matus Ferech1,
- Samuel Coenen1,2,
- Peter Stephens4, and
- European Surveillance of Antimicrobial Consumption Project Groupa
- 1University of Antwerp, Antwerp
- 2Research Foundation—Flanders, Brussels, Belgium
- 3University of Leiden, Leiden, The Netherlands
- 4IMS Health, London, United Kingdom
- Reprints or correspondence: Dr. Herman Goossens, Laboratory of Microbiology, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium (Herman.Goossens{at}uza.be).
Abstract
The European Surveillance of Antimicrobial Consumption (ESAC) project collects data on antibacterial use in Europe, applying the Anatomic Therapeutic Chemical classification system and defined daily dose methodology, as recommended by the World Health Organization. Comparable data for the United States have been collected from IMS Health. The IMS Health sales data, processed according to ESAC methodology, suggest that outpatient antibacterial use in the United States is high (only 3 of 27 European countries used more) and is mainly characterized by a shift towards newer antibiotics.
Footnotes
-
The information contained in this publication does not necessarily reflect the opinion or the position of the European Commission.
- Received September 18, 2006.
- Accepted December 22, 2006.
- © 2007 Infectious Diseases Society of America
